<?xml version="1.0" encoding="UTF-8"?>
<p>Specific mutations were engineered in expression pCAGGS plasmids derived from the CAL strain using the QuickChangeTM site-directed mutagenesis kit (Stratagene) as recommended by the manufacturer. These materials were developed using the Licensed technology (Kawaoka-P99264US Recombinant Influenza viruses for vaccines and gene therapy).</p>
